Eyal Desheh became the Israel-based drugmaker's CFO in 2008.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Estimates for erenumab annual sales run as high as $2.3 billion.
It is being reported that Teva will lose its CFO.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.